Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) gained after a European agency advanced a diabetes treatment that the company developed with Sanofi SA (NASDAQ:SNY). The European Medicines Agency’s Committee for Medicinal Products for Human Use recommended approval of sotagliflozin in the EU for both a 200- and 400-milligram dose as part of insulin therapy to improve blood sugar control in some adults with Type 1 diabetes.
Shares of Lexicon were up 27% to $6.76 in Nasdaq trading. Sanofi gained 1.4% to $42.20.
Colony Capital Inc (NYSE:CLNY) dropped after the Los Angeles-based financial services company reported fourth-quarter net investment losses of $29 million. Total revenue dropped to $634 million from $720 million a year earlier.
The stock was down 3.6% to $5.36 in New York.
Puma Biotechnology Inc (NASDAQ:PBYI) surged after the biopharmaceutical company beat Wall Street’s fourth-quarter estimates thanks to sales of its flagship breast-cancer drug Nerlynx. The company’s net loss shrank to $0.32 per share from $1.03 a year earlier. It posted revenue of $71.1 million, of which $61.1 million was from Nerlynx and $10 million was from license revenue. Analysts had expected Puma to lose $0.69 on revenue of $53.65 million.
Shares climbed 40% to $39.02 in Nasdaq trading.
Intrexon Corp (NASDAQ:XON) sank after the Germantown, Maryland, biotech posted a fourth-quarter loss $0.21 per basic share on total revenue of $43.2 million, a decrease of 44% from a year earlier. Cash, cash equivalents and short-term investments totaled $222.5 million.
The stock tumbled 36% to $5.09 on the Nasdaq.
The Russell 2000 index of small-cap stocks edged up 0.3% to 1580.26.
Contact Dennis Fitzgerald at [email protected]